Arbutus Biopharma Corp at JMP Securities Life Sciences Conference (Virtual) Transcript
All right. Thank you, everyone, for joining us for the first day of the JMP Securities Life Sciences Conference. My name is Roy Buchanan, biotech analyst. And our first presenting company we have is Arbutus Biopharma. I have most of the team here -- Dave Hastings, CFO; Gaston Picchio, Chief Development Officer; and Mike Sofia, Chief Scientific Officer -- to tell us the story about Arbutus.
Questions & Answers
I'm actually going to start with Dave. So Dave, why don't you just remind us where cash was at the end of the last quarter, what you guided for runway, and how you're thinking about funding the next couple years as you ramp up the programs.
Yeah. Thanks, Roy, and good morning, everybody. And Roy, thanks for hosting us today. We ended the first quarter of 2022 with $222 million in cash, which gives us about two years of runway into Q2 of 2024. So we've had significant
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |